文献速递认知障碍与痴呆

C反应蛋白对APOE ε4纯合子携带者认知与阿尔茨海默病生物标志物的影响

Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE ɛ4 Carriers.
PubMed 文献 · Neurology · 2021-09-20

基于ADNI队列566名参与者,分析血浆CRP与APOE基因型对认知和AD生物标志物的交互作用。仅在2个APOE ε4等位基因携带者中,CRP升高与基线及12个月MMSE评分较低相关,且与CSF t-Tau和p-Tau升高交互相关;无APOE ε4等位基因者中CRP升高与CSF t-Tau和p-Tau降低相关。

要点

  • 在APOE ε4纯合子中,血浆CRP升高与认知评分较低相关。
  • APOE ε4纯合子与CRP升高交互增加CSF t-Tau和p-Tau水平。
  • 无APOE ε4等位基因者中CRP升高与CSF tau降低相关。

核心结论

  • 外周炎症释放的CRP可能是APOE ε4相关AD神经退行性变的中介因素,并可作为AD的药物靶点。

研究设计与样本

  • 分析阿尔茨海默病神经影像学倡议(ADNI)研究数据,纳入566名参与者,检测APOE基因型、血浆CRP、诊断状态、MMSE和CDR评分、CSF Aβ42、t-Tau、p-Tau及淀粉样蛋白PET。
  • 采用多变量回归分析检验血浆CRP与APOE对认知和生物标志物结局的关联。

主要发现

  • 274名(48.4%)无APOE ε4等位基因,222名(39.2%)有1个,70名(12.4%)有2个。
  • 仅在2个APOE ε4等位基因携带者中,调整性别、年龄和教育后,CRP升高与基线MMSE较低相关(β -0.52,95%CI -1.01至-0.12),与12个月随访MMSE较低相关(β -1.09,95%CI -1.88至-0.17)。
  • 2个APOE ε4等位基因与血浆CRP升高的交互作用与CSF t-Tau升高(β=11.21,SE 3.37,p<0.001)和p-Tau升高(β=+2.74,SE 1.14,p<0.01)相关。
  • 在无APOE ε4等位基因者中,CRP升高与CSF t-Tau和p-Tau降低相关。
  • 这些效应在12个月随访时更强。

临床怎么用

  • 在APOE ε4纯合子携带者中,监测血浆CRP可能有助于评估AD神经退行性变风险。
  • CRP作为外周炎症标志物,可能成为APOE ε4相关AD的潜在药物靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Previous research has shown that elevated blood C-reactive protein (CRP) is associated with increased Alzheimer disease (AD) risk only in APOE ε4 allele carriers; the objective of this study was to examine the interactive effects of plasma CRP and APOE genotype on cognition and AD biomarkers. METHODS: Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study were analyzed, including APOE genotype; plasma CRP concentrations; diagnostic status (i.e., mild cognitive impairment and dementia due to AD); Mini-Mental State Examination (MMSE) and Clinical Dementia Rating Dementia Staging Instrument scores; CSF concentrations of β-amyloid peptide (Aβ42), total tau (t-Tau) and phosphorylated tau (p-Tau); and amyloid (AV45) PET imaging. Multivariable regression analyses tested the associations between plasma CRP and APOE on cognitive and biomarker outcomes. RESULTS: Among 566 ADNI participants, 274 (48.4%) had no, 222 (39.2%) had 1, and 70 (12.4%) had 2 APOE ε4 alleles. Among only participants who had 2 APOE ε4 alleles, elevated CRP was associated with lower MMSE score at baseline (β [95% confidence interval] -0.52 [-1.01, -0.12]) and 12-month follow-up (β -1.09 [-1.88, -0.17]) after adjustment for sex, age, and education. The interaction of 2 APOE ε4 alleles and elevated plasma CRP was associated with increased CSF levels of t-Tau (β = 11.21, SE 3.37, p < 0.001) and p-Tau (β = +2.74, SE 1.14, p < 0.01). Among those who had no APOE ε4 alleles, elevated CRP was associated with decreased CSF t-Tau and p-Tau. These effects were stronger at the 12-month follow-up. DISCUSSION: CRP released during peripheral inflammation could be a mediator in APOE ε4-related AD neurodegeneration and serve as a drug target for AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tao Q, Alvin Ang TF, Akhter-Khan SC, et al. Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE ɛ4 Carriers. Neurology. 2021. PMID: 34266923. doi:10.1212/WNL.0000000000012512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。